Description

HGH Fragment 176-191 – Prefilled Laboratory Cartridge for In Vitro Research (20 mg / 3 ml) Synthetic peptide fragment corresponding to the carboxy-terminal sequence of human growth hormone (amino acids 176–191) in a pre-prepared stabilized buffered solution for in vitro research of lipolytic activity, inhibition of lipogenesis, metabolic pathways, and cellular signaling in adipocytes.

Overview and Mechanism of Action (In Vitro) HGH Fragment 176-191 is a specifically designed sequence that separates the primary metabolic and lipolytic effects of growth hormone from its overall somatotropic action (it does not promote tissue growth or affect insulin sensitivity across the full scope of the whole hormone). In experimental endocrinology, cell biology, and adipose tissue metabolism research, it serves as a standard reference substance:

• Stimulation of lipolysis in adipocytes in vitro: Activates triglyceride breakdown and the release of free fatty acids in isolated fat cells through the modulation of specific receptors and intracellular signaling cascades.
• Inhibition of lipogenesis: Blocks the process of fat formation and storage in primary and cultured adipocytes by suppressing key enzymes responsible for fatty acid synthesis.
• Metabolic selectivity: Studies show that fragment 176-191 specifically affects lipid metabolism without inducing hyperglycemic or mitogenic effects associated with the full somatotropin molecular chain.
• Ready-to-use format for precise laboratory dosing: The stabilized liquid format in a 3 ml cartridge eliminates variability associated with manual reconstitution of lyophilized peptides, ensuring high stability, accuracy, and reproducibility during micro-dosing in laboratory systems.

Technical and Chemical Specification

• Classification: Lipolytic peptide / Synthetic growth hormone fragment / Research peptide solution (RUO)
• Product format: Prefilled calibrated laboratory cartridge (3 ml volume)
• Substance content: 20 mg / 3 ml (concentration approx. 6.67 mg/ml)
• Amino acid sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (with stabilized disulfide bridge cyclization between cysteines)
• Molecular formula: C78H123N23O23S2
• Form: Sterile stabilized solution / Ready-to-Use for direct laboratory application
• Solution matrix: Sterile buffered isotonic solution for laboratory use (optimized pH, no reconstitution required)
• Compatibility: Designed for standard laboratory pen injectors and dispensers for 3 ml cartridges (pen injector / dispenser not included)
• Storage conditions: Store at 2–8 °C in a dark and cold place. Protect from freezing. Maintain the laboratory cold chain to preserve standard stability.

Professional Sources and Literature

• Ng, F. M., et al. Metabolic studies of a synthetic lipolytic domain (hGH 177-191) of the human growth hormone. Hormone and Metabolic Research, 2000.
• Jiang, W. J., et al. Lipolytic and anti-lipogenic effects of the growth hormone fragment hGH 176-191 in cellular models. Journal of Peptide Research, 2004.
• Heffernan, M. A., et al. The effects of the lipolytic peptide hGH 176-191 on lipid metabolism and body fat accumulation in experimental models. Endocrinology, 2001.

Legal Disclaimer and Terms of Purchase This product is classified and supplied exclusively for laboratory, scientific, and in vitro research purposes (Research Use Only – RUO). The stabilized peptide solution and mechanical cartridge are not a medicinal product, drug, weight-loss preparation, dietary supplement, or substance intended for human or veterinary consumption, oral ingestion, injection, or diagnostic procedures. By submitting an order, the buyer explicitly confirms that they have reached the age of at least 18 years, possess adequate laboratory infrastructure and personnel equipment for safe handling of research chemicals, and are fully familiar with laboratory safety protocols. The seller assumes no liability for any improper or unapproved use.